MRVL.V - Marvel Biosciences Corp.

Marvel Biosciences Corp.

505 8th Avenue S.W.
Suit 420
Calgary, AB T2P 1G2
Canada

https://marvelbiotechnology.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. J. Roderick Matheson	Exec. Chairman & CEO	150k	N/A	N/A
Dr. Mark Williams M.B.A., Ph.D.	Pres, Chief Science Officer & Director	150k	N/A	1972
Mr. Harpreet Nijjar C.M.A., CPA	Chief Financial Officer	37.57k	N/A	1988
Ms. Jacqueline Groot	Corp. Sec.	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002) and MB-204 an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.

Corporate Governance

Marvel Biosciences Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.